CoChat

Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Muscular dystrophy-associated mutations of TRIM32 impair ULK1-dependent autophagy response during muscle atrophy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aau8857

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TRIM32 binds to AMBRA1. (A) Protein extracts from MYC-AMBRA1– and FLAG-TRIM32–transfected 293 T cells were subjected to immunoprecipitation (IP) using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-MYC and anti-TRIM32 antibodies. (B) Undifferentiated and differentiated C2.7 cells were lysed, and protein extracts were immunoprecipitated using an anti-TRIM32 antibody. An unrelated antibody was used as a negative control (IP Ctr). Immunopurified complexes were analyzed by immunoblotting using anti-AMBRA1 and anti-TRIM32 antibodies. (C) 293 T cells were cotransfected with vectors encoding HA-TRIM32 and the following MYC-AMBRA1 constructs: full length (FL), N-terminal (amino acids 1 to 532), central (amino acids 533 to 751), and C-terminal region (amino acids 767 to 1269). Protein extracts were immunoprecipitated using an anti-MYC antibody. Immunopurified complexes were analyzed by immunoblotting using anti-HA and anti-MYC antibodies. A scheme of the AMBRA1 domain architecture is shown (P-rich, proline-rich domain; S-rich, serine-rich domain; BH3, Bcl2 homology 3 domain). The red bar indicates the TRIM32-interacting domain. Asterisks indicate bands of AMBRA1 at the expected molecular weights. (D) TRIM32 KO 293 T cells were cotransfected with vectors encoding MYC-AMBRA1 and the following FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 to 136), central region containing the coiled-coil domain (amino acids 136 to 326), and NHL repeats (amino acid 327 to 653). Protein extracts were immunoprecipitated using anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the TRIM32 domain architecture is shown (CC, coiled-coil domain). The red bar indicates the AMBRA1-interacting domain.
Fig. 1 TRIM32 binds to AMBRA1. (A) Protein extracts from MYC-AMBRA1– and FLAG-TRIM32–transfected 293 T cells were subjected to immunoprecipitation (IP) using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-MYC and anti-TRIM32 antibodies. (B) Undifferentiated and differentiated C2.7 cells were lysed, and protein extracts were immunoprecipitated using an anti-TRIM32 antibody. An unrelated antibody was used as a negative control (IP Ctr). Immunopurified complexes were analyzed by immunoblotting using anti-AMBRA1 and anti-TRIM32 antibodies. (C) 293 T cells were cotransfected with vectors encoding HA-TRIM32 and the following MYC-AMBRA1 constructs: full length (FL), N-terminal (amino acids 1 to 532), central (amino acids 533 to 751), and C-terminal region (amino acids 767 to 1269). Protein extracts were immunoprecipitated using an anti-MYC antibody. Immunopurified complexes were analyzed by immunoblotting using anti-HA and anti-MYC antibodies. A scheme of the AMBRA1 domain architecture is shown (P-rich, proline-rich domain; S-rich, serine-rich domain; BH3, Bcl2 homology 3 domain). The red bar indicates the TRIM32-interacting domain. Asterisks indicate bands of AMBRA1 at the expected molecular weights. (D) TRIM32 KO 293 T cells were cotransfected with vectors encoding MYC-AMBRA1 and the following FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 to 136), central region containing the coiled-coil domain (amino acids 136 to 326), and NHL repeats (amino acid 327 to 653). Protein extracts were immunoprecipitated using anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the TRIM32 domain architecture is shown (CC, coiled-coil domain). The red bar indicates the AMBRA1-interacting domain.CC BY-NC · PubMed Central
Fig. 2 Trim32 is required for autophagy induction by atrophic stimuli in muscle cells. (A) shCTR and shTrim32 C2.7 cells differentiated for 3 days were treated with dexamethasone (dexa) for 4 hours (h) or left untreated. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A (E64d/PepA), as indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting (left). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was included as a loading control. The graph (right) reports means ± SD of LC3-II/GAPDH values from three independent experiments; *P < 0.05. (B) Differentiated shCTR and shTrim32 C2.7 cells were treated with dexamethasone for 4 hours and processed for EM. ER, endoplasmic reticulum; N, nucleus. Yellow asterisks highlight degradative compartments (amphisomes, lysosomes, and autolysosomes). Scale bars, 1 μm. The graph (right) reports means ± SEM of degradative vacuoles per cell per section. Images of untreated cells are reported in fig. S3B. (C) WT (Trim32+/+) and KO (Trim32−/−) mice were injected with dexamethasone (5 mg/kg) or saline solution (0.9% NaCl) as a negative control. Mice were sacrificed 8 hours after injection, and protein extracts were prepared from quadricep muscles. LC3-II, NBR1, and p62 levels were analyzed by immunoblotting (left). Arrows point to TRIM32- and NBR1-specific bands; the number sign (#) indicates nonspecific signals. The graph (right) reports means ± SD of LC3-II/GAPDH, NBR1/GAPDH, and p62/GAPDH values from at least three independent experiments; *P < 0.05.
Fig. 2 Trim32 is required for autophagy induction by atrophic stimuli in muscle cells. (A) shCTR and shTrim32 C2.7 cells differentiated for 3 days were treated with dexamethasone (dexa) for 4 hours (h) or left untreated. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A (E64d/PepA), as indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting (left). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was included as a loading control. The graph (right) reports means ± SD of LC3-II/GAPDH values from three independent experiments; *P < 0.05. (B) Differentiated shCTR and shTrim32 C2.7 cells were treated with dexamethasone for 4 hours and processed for EM. ER, endoplasmic reticulum; N, nucleus. Yellow asterisks highlight degradative compartments (amphisomes, lysosomes, and autolysosomes). Scale bars, 1 μm. The graph (right) reports means ± SEM of degradative vacuoles per cell per section. Images of untreated cells are reported in fig. S3B. (C) WT (Trim32+/+) and KO (Trim32−/−) mice were injected with dexamethasone (5 mg/kg) or saline solution (0.9% NaCl) as a negative control. Mice were sacrificed 8 hours after injection, and protein extracts were prepared from quadricep muscles. LC3-II, NBR1, and p62 levels were analyzed by immunoblotting (left). Arrows point to TRIM32- and NBR1-specific bands; the number sign (#) indicates nonspecific signals. The graph (right) reports means ± SD of LC3-II/GAPDH, NBR1/GAPDH, and p62/GAPDH values from at least three independent experiments; *P < 0.05.CC BY-NC · PubMed Central
Fig. 3 TRIM32 associates with ULK1 in an AMBRA1-dependent manner. (A) Protein extracts from 293 T cells transfected with vectors encoding HA-TRIM32, FLAG–BECLIN 1, and MYC-ULK1, as indicated, were subjected to immunoprecipitation using an anti-HA antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG, anti-MYC, and anti-HA antibodies. (B) TRIM32 KO 293 T cells were cotransfected with vectors encoding MYC-ULK1 and the following FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 to 133), central region containing the coiled-coil domain (amino acids 134 to 198), and NHL repeats (amino acids 199 to 325). Protein extracts were immunoprecipitated using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the TRIM32 domain architecture is shown; the red bar indicates the ULK1-interacting domain. (C) Control shRNA and shAmbra1 293 T cells were transfected with a vector encoding MYC-ULK1, alone or in combination with FLAG-TRIM32. Cells were lysed, and protein extracts were subjected to immunoprecipitation using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-MYC and anti-FLAG antibodies. Total extracts were also probed with an anti-AMBRA1 antibody to verify AMBRA1 silencing.
Fig. 3 TRIM32 associates with ULK1 in an AMBRA1-dependent manner. (A) Protein extracts from 293 T cells transfected with vectors encoding HA-TRIM32, FLAG–BECLIN 1, and MYC-ULK1, as indicated, were subjected to immunoprecipitation using an anti-HA antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG, anti-MYC, and anti-HA antibodies. (B) TRIM32 KO 293 T cells were cotransfected with vectors encoding MYC-ULK1 and the following FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 to 133), central region containing the coiled-coil domain (amino acids 134 to 198), and NHL repeats (amino acids 199 to 325). Protein extracts were immunoprecipitated using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the TRIM32 domain architecture is shown; the red bar indicates the ULK1-interacting domain. (C) Control shRNA and shAmbra1 293 T cells were transfected with a vector encoding MYC-ULK1, alone or in combination with FLAG-TRIM32. Cells were lysed, and protein extracts were subjected to immunoprecipitation using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-MYC and anti-FLAG antibodies. Total extracts were also probed with an anti-AMBRA1 antibody to verify AMBRA1 silencing.CC BY-NC · PubMed Central
Fig. 4 TRIM32 stimulates ULK1 activity in an AMBRA1-dependent manner through unanchored K63-linked polyubiquitin. (A) Protein extracts from FLAG-TRIM32–transfected 293 T cells were subjected to immunoprecipitation using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect ULK1 and K63-linked ubiquitin. Total extracts were also probed with an anti-FLAG antibody to verify TRIM32 transfection. (B) In vitro ULK1 ubiquitination assay using immunopurified Flag TRIM32 and recombinant ULK1, HA ubiquitin, E1 Ub–activating enzyme (UBE1), and E2 Ub–conjugating enzyme (UBE2N). Reactions were also performed in the absence of UBE1 to verify ubiquitination reaction specificity. At the end of the reaction, ULK1 was immunopurified and ubiquitination evaluated by immunoblotting using an anti-HA antibody (lanes 1 and 2). To verify whether ubiquitin was covalently linked, immunopurified ULK1 was boiled in 1% SDS after the ubiquitination reaction, reimmunoprecipitated (Re-IP), and analyzed by immunoblotting using anti-HA and anti-ULK1 antibodies (lanes 3 and 4). (C) shCtr or shAmbra1 293 T cells were transfected with a vector encoding FLAG-TRIM32 or an empty vector (−). Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect ULK1 and K63-linked ubiquitin. Total extracts were also probed with FLAG and AMBRA1 antibodies to verify TRIM32 transfection and AMBRA1 silencing, respectively. (D) 293 T cells were transfected with vectors encoding HA-tagged ubiquitin, FLAG-ULK1, and TRIM32, as indicated. Protein extracts were subjected to immunoprecipitation using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting to detect K63-linked ubiquitin and ULK1 using specific antibodies. TRIM32 expression was also analyzed in total extracts. To verify whether ubiquitin was covalently linked, immunopurified FLAG-ULK1 was boiled in 1% SDS, reimmunoprecipitated, and analyzed by immunoblotting using anti–K63-linked ubiquitin and anti-ULK1 antibodies. (E) 293 T cells were transfected with vectors encoding FLAG-VPS34, alone or in combination with HA-TRIM32. TRIM32, VPS34, and phospho-VSP34 [pVPS34; Ser249 (S249)] were analyzed by immunoblotting. GAPDH was included as a loading control. (F) 293 T cells were transfected with vectors encoding FLAG–BECLIN 1, alone or in combination with HA-TRIM32. The levels of TRIM32, BECLIN 1, and phospho–BECLIN 1 [pBECLIN 1; Ser15 (S15)] were analyzed by immunoblotting. GAPDH was included as a loading control.
Fig. 4 TRIM32 stimulates ULK1 activity in an AMBRA1-dependent manner through unanchored K63-linked polyubiquitin. (A) Protein extracts from FLAG-TRIM32–transfected 293 T cells were subjected to immunoprecipitation using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect ULK1 and K63-linked ubiquitin. Total extracts were also probed with an anti-FLAG antibody to verify TRIM32 transfection. (B) In vitro ULK1 ubiquitination assay using immunopurified Flag TRIM32 and recombinant ULK1, HA ubiquitin, E1 Ub–activating enzyme (UBE1), and E2 Ub–conjugating enzyme (UBE2N). Reactions were also performed in the absence of UBE1 to verify ubiquitination reaction specificity. At the end of the reaction, ULK1 was immunopurified and ubiquitination evaluated by immunoblotting using an anti-HA antibody (lanes 1 and 2). To verify whether ubiquitin was covalently linked, immunopurified ULK1 was boiled in 1% SDS after the ubiquitination reaction, reimmunoprecipitated (Re-IP), and analyzed by immunoblotting using anti-HA and anti-ULK1 antibodies (lanes 3 and 4). (C) shCtr or shAmbra1 293 T cells were transfected with a vector encoding FLAG-TRIM32 or an empty vector (−). Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect ULK1 and K63-linked ubiquitin. Total extracts were also probed with FLAG and AMBRA1 antibodies to verify TRIM32 transfection and AMBRA1 silencing, respectively. (D) 293 T cells were transfected with vectors encoding HA-tagged ubiquitin, FLAG-ULK1, and TRIM32, as indicated. Protein extracts were subjected to immunoprecipitation using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting to detect K63-linked ubiquitin and ULK1 using specific antibodies. TRIM32 expression was also analyzed in total extracts. To verify whether ubiquitin was covalently linked, immunopurified FLAG-ULK1 was boiled in 1% SDS, reimmunoprecipitated, and analyzed by immunoblotting using anti–K63-linked ubiquitin and anti-ULK1 antibodies. (E) 293 T cells were transfected with vectors encoding FLAG-VPS34, alone or in combination with HA-TRIM32. TRIM32, VPS34, and phospho-VSP34 [pVPS34; Ser249 (S249)] were analyzed by immunoblotting. GAPDH was included as a loading control. (F) 293 T cells were transfected with vectors encoding FLAG–BECLIN 1, alone or in combination with HA-TRIM32. The levels of TRIM32, BECLIN 1, and phospho–BECLIN 1 [pBECLIN 1; Ser15 (S15)] were analyzed by immunoblotting. GAPDH was included as a loading control.CC BY-NC · PubMed Central
Fig. 5 TRIM32 is required for ULK1 activation through K63-linked polyubiquitin upon dexamethasone treatment. (A) FLAG-TRIM32–expressing C2.7 cells differentiated for 3 days were treated with dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1 using specific antibodies. (B) C2.7 cells differentiated for 3 days were treated with dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of ULK1 and K63-linked polyubiquitin. An unrelated antibody was used as a negative control (IP CTR). (C) shCTR and shTrim32 C2.7 cells differentiated for 3 days were treated with dexamethasone for 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of ULK1 and K63-linked ubiquitin. An unrelated antibody was used as a negative control. Total extracts were probed with an anti-TRIM32 antibody to verify silencing efficiency. (D) BECLIN 1 overexpressing Trim32 WT and KO C2.7 cells were differentiated for 3 days and incubated with dexamethasone or nutrient-deprived medium (Starv) for 2 hours. Protein extracts were analyzed by immunoblotting to measure the levels of phospho–BECLIN 1 [pBCN 1 (Ser15)], BECLIN 1, and TRIM32. GAPDH was included as a loading control. (E) Trim32 WT and KO C2.7 cells differentiated for 3 days were incubated with dexamethasone for 2 hours. Cells were lysed, and protein extracts were analyzed by immunoblotting to measure the levels of phospho-ATG14 [pATG14 (Ser29)], ATG14, and TRIM32. GAPDH was included as a loading control.
Fig. 5 TRIM32 is required for ULK1 activation through K63-linked polyubiquitin upon dexamethasone treatment. (A) FLAG-TRIM32–expressing C2.7 cells differentiated for 3 days were treated with dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1 using specific antibodies. (B) C2.7 cells differentiated for 3 days were treated with dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of ULK1 and K63-linked polyubiquitin. An unrelated antibody was used as a negative control (IP CTR). (C) shCTR and shTrim32 C2.7 cells differentiated for 3 days were treated with dexamethasone for 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of ULK1 and K63-linked ubiquitin. An unrelated antibody was used as a negative control. Total extracts were probed with an anti-TRIM32 antibody to verify silencing efficiency. (D) BECLIN 1 overexpressing Trim32 WT and KO C2.7 cells were differentiated for 3 days and incubated with dexamethasone or nutrient-deprived medium (Starv) for 2 hours. Protein extracts were analyzed by immunoblotting to measure the levels of phospho–BECLIN 1 [pBCN 1 (Ser15)], BECLIN 1, and TRIM32. GAPDH was included as a loading control. (E) Trim32 WT and KO C2.7 cells differentiated for 3 days were incubated with dexamethasone for 2 hours. Cells were lysed, and protein extracts were analyzed by immunoblotting to measure the levels of phospho-ATG14 [pATG14 (Ser29)], ATG14, and TRIM32. GAPDH was included as a loading control.CC BY-NC · PubMed Central
Fig. 6 TRIM32 pathological mutants are unable to interact with ULK1 and promote autophagy. (A) 293 T cells were transfected with a vector encoding for MYC-ULK1, alone or in combination with HA-TRIM32 WT, or the indicated pathogenic TRIM32 mutants. Protein extracts were subjected to immunoprecipitation using an anti-HA antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1. (B) TRIM32 KO C2.7 cells were infected with retroviruses encoding WT FLAG-TRIM32 or the indicated pathogenic TRIM32 mutants. EMPTY, TRIM32 KO C2.7 cells infected with noncoding retroviruses. Upon 3 days in differentiation medium, cells were treated with dexamethasone for 4 hours and incubated with the lysosome inhibitors E64d and pepstatin A for 1 hour before lysis, as indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting using specific antibodies. GAPDH was included as a loading control. (C) Fibroblasts from a WT donor and a patient with LGMD2H were transdifferentiated to myoblasts by MYOD (myogenic differentiation 1) ectopic expression. Cells differentiated for 3 days were treated, or not, with dexamethasone for 2 and 4 hours. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A, as indicated. LC3-II and myosin heavy chain (MYOSIN HC) levels were analyzed by immunoblotting (bottom panel). GAPDH was included as a loading control.
Fig. 6 TRIM32 pathological mutants are unable to interact with ULK1 and promote autophagy. (A) 293 T cells were transfected with a vector encoding for MYC-ULK1, alone or in combination with HA-TRIM32 WT, or the indicated pathogenic TRIM32 mutants. Protein extracts were subjected to immunoprecipitation using an anti-HA antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1. (B) TRIM32 KO C2.7 cells were infected with retroviruses encoding WT FLAG-TRIM32 or the indicated pathogenic TRIM32 mutants. EMPTY, TRIM32 KO C2.7 cells infected with noncoding retroviruses. Upon 3 days in differentiation medium, cells were treated with dexamethasone for 4 hours and incubated with the lysosome inhibitors E64d and pepstatin A for 1 hour before lysis, as indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting using specific antibodies. GAPDH was included as a loading control. (C) Fibroblasts from a WT donor and a patient with LGMD2H were transdifferentiated to myoblasts by MYOD (myogenic differentiation 1) ectopic expression. Cells differentiated for 3 days were treated, or not, with dexamethasone for 2 and 4 hours. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A, as indicated. LC3-II and myosin heavy chain (MYOSIN HC) levels were analyzed by immunoblotting (bottom panel). GAPDH was included as a loading control.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

Metadata

Authors
Di Rienzo, M., Antonioli, M., Fusco, C., Liu, Y., Mari, M., Orhon, I., Refolo, G., Germani, F., Corazzari, M., Romagnoli, A., Ciccosanti, F., Mandriani, B., Pellico, M. T., De La Torre, R., Ding, H., Dentice, M., Neri, M., Ferlini, A., Reggiori, F., Kulesz-Martin, M., Piacentini, M., Merla, G., & Fimia, G. M.
Affiliations
  • National Institute for Infectious Diseases IRCCS, Lazzaro Spallanzani, 00149 Rome, Italy.
  • Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
  • Casa Sollievo della Sofferenza (IT)
  • Oregon Health & Science University (US)
  • University Medical Center Groningen (NL)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • Department of Dermatology, Oregon Health and Science University, Portland, OR 97239, USA.
  • University of Manitoba (CA)
  • University of Naples Federico II (IT)
  • University of Ferrara (IT)
  • University of Rome Tor Vergata (IT)
  • University of Salento (IT)
Corresponding author
  • Piacentini, M.
  • Fimia, G. M.
Venue
Science Advances
Published
2019-05-03
Volume
5
Issue
5
Pages
eaau8857-eaau8857
ISSN
2375-2548 (ISSN-L)
OpenAlex
W2944528098
Cited by
107
References
65
Citations by year
2026: 10 · 2025: 10 · 2024: 17 · 2023: 7 · 2022: 15 · 2021: 18 · 2020: 23 · 2019: 7
FWCI
5.21
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by-nc)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR070645)
  • H2020 Marie Skłodowska-Curie Actions (713660, 765912)
  • Netherlands Organisation for Health Research and Development (016.130.606)
  • Fondazione Telethon (GEP12072)
  • Associazione Italiana per la Ricerca sul Cancro (17404, 15244)
  • ALW Open Programme (ALWOP.310)
  • ZonMW TOP grant (91217002)
  • Regione Lazio (Gruppi di Ricerca 2018)
  • Fondazione Fibrosi Cistica (FFC#8/2018)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
TRIM32, ULK1, muscle atrophy, K63-linked polyubiquitin, ubiquitin ligase, AMBRA1, MuRF1, reactive oxygen species, muscular dystrophy
MeSH terms
Autophagy-Related Protein-1 Homolog, Animals, Autophagy, Cell Line, Humans, Lysine, Protein Binding, Mice, Knockout, Myoblasts, RNA Interference, RNA, Small Interfering, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing, Muscular Dystrophies, Limb-Girdle, Mice, Cell Transdifferentiation, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.